Marinus Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
MRNS Marinus Pharmaceuticals Inc
RVLP RVL Pharmaceuticals PLC
NAUT Nautilus Biotechnology Inc
BOF BranchOut Food Inc
SPRC Scisparc Ltd
NRSN Neurosense Therapeutics Ltd
ACNT Ascent Industries Co
FATH Fathom Digital Manufacturing Corp
PAYX Paychex Inc
WAVD Wavedancer Inc

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of therapeutics for seizure disorders. The Company’s commercial product, ZTALMY (ganaxolone) oral suspension CV, has been approved by the United States Food and Drug Administration (FDA) for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase III trials in tuberous sclerosis complex and refractory status epilepticus. The Company's ganaxolone is a neuroactive steroid gamma-aminobutyric acid type A (GABAA) receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. Its ganaxolone is also being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.


Last Trade
-0.02 (-0.24%)
B/A Size

Market Hours

Closing Price
Day's Change
-0.17 (-2.06%)
Bid close
Ask close
B/A Size
Day's High
Day's Low

10-day average volume:

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.